Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


05.08.2019

1 Anticancer Res
1 Biochem Biophys Res Commun
1 Br J Cancer
2 Br J Dermatol
4 Clin Cancer Res
1 Gene
1 Int J Cancer
2 J Am Acad Dermatol
1 J Invest Dermatol
2 Lancet Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. VALENTINI V, Zelli V, Gaggiano E, Silvestri V, et al
    MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas.
    Anticancer Res. 2019;39:4085-4093.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  2. MINAMI K, Ueda N, Maeda H, Ishimoto K, et al
    Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA5 in melanoma cells treated with anticancer drugs.
    Biochem Biophys Res Commun. 2019 Jul 27. pii: S0006-291X(19)31446.
    PubMed     Text format     Abstract available


    Br J Cancer

  3. CHESNEY J, Puzanov I, Collichio F, Milhem MM, et al
    Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.
    Br J Cancer. 2019 Jul 29. pii: 10.1038/s41416-019-0530.
    PubMed     Text format     Abstract available


    Br J Dermatol

  4. RIBERO S
    Synergy between MC1R mutations and a high naevus count in increasing melanoma risk in the general population.
    Br J Dermatol. 2019 Jul 28. doi: 10.1111/bjd.18301.
    PubMed     Text format    

  5. GAMBICHLER T, Schroter U, Hoxtermann S, Susok L, et al
    Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade.
    Br J Dermatol. 2019 Jul 30. doi: 10.1111/bjd.18379.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  6. HAMID O, Molinero L, Bolen CR, Sosman JA, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-18-3488.
    PubMed     Text format     Abstract available

  7. PENG W, Williams LJ, Xu C, Melendez B, et al
    Anti-OX40 antibody directly enhances the function of tumor-reactive CD8(+) T cells and synergizes with PI3Kbeta inhibition in PTEN loss melanoma.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-1259.
    PubMed     Text format     Abstract available

  8. ALOIA A, Mullhaupt D, Chabbert CD, Eberhart T, et al
    A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0253.
    PubMed     Text format     Abstract available

  9. KONG Y, Yu J, Yan J, Guo Q, et al
    Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0475.
    PubMed     Text format     Abstract available


    Gene

  10. YANG Q, Deng Y, Xu Y, Ding N, et al
    Knockdown of SSATX, an alternative splicing variant of the SAT1 gene, promotes melanoma progression.
    Gene. 2019 Jul 25:144010. doi: 10.1016/j.gene.2019.144010.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. FURFARO AL, Ottonello S, Loi G, Cossu I, et al
    HO-1 downregulation favors BRAF(V600) melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition.
    Int J Cancer. 2019 Aug 3. doi: 10.1002/ijc.32611.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  12. MAGDALENO-TAPIAL J, Valenzuela-Onate C, Ortiz-Salvador JM, Martinez-Domenech A, et al
    Acral Melanoma with Eccrine Involvement: Comments and Controversies.
    J Am Acad Dermatol. 2019 Jul 25. pii: S0190-9622(19)32453.
    PubMed     Text format     Abstract available

  13. KNACKSTEDT TJ, Baltz JO, Wilmer EN, Jellinek NJ, et al
    Research Letter: Assessing Patient Outcomes After Digit Sparing En Bloc Surgery of Nail Apparatus Melanoma In Situ Using Two Validated Surveys.
    J Am Acad Dermatol. 2019 Jul 23. pii: S0190-9622(19)32436.
    PubMed     Text format    


    J Invest Dermatol

  14. LEACHMAN SA, Hornyak TJ, Barsh G, Bastian BC, et al
    Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting.
    J Invest Dermatol. 2019 Jul 23. pii: S0022-202X(19)32550.
    PubMed     Text format    


    Lancet Oncol

  15. HASSEL JC
    5-year results for pembrolizumab treatment of advanced melanoma.
    Lancet Oncol. 2019 Jul 22. pii: S1470-2045(19)30483.
    PubMed     Text format    

  16. ROBERT C, Ribas A, Schachter J, Arance A, et al
    Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
    Lancet Oncol. 2019 Jul 22. pii: S1470-2045(19)30388.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: